Document is current
Any future updates will be listed below
-
Authors
Murthy, Vishnu
Aggarwal, Rahul
Koo, Phillip J.
- License Information
-
More Information
Article History
Accepted: 19 September 2021
First Online: 20 January 2022
Declarations
:
: Vishnu Murthy declares that he has no conflict of interest. Rahul Aggarwal is a participant on a scientific advisory board for Novartis (for its ongoing Phase 3 study of CTT1057 PSMA PET in prostate cancer). Phillip J. Koo has received compensation for service as a consultant from Bayer, Progenics Pharmaceuticals, Blue Earth Diagnostics, Advanced Accelerator Applications, Janssen, and Astellas; and has received speaker's honoraria from Bayer, Janssen, Advanced Accelerator Applications, Progenics, Merck, and AstraZeneca.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
